Trial Profile

A Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics and efficacy of HRS-8080 or SHR-A2009 combined with anti-tumor therapy in patients with unresectable or metastatic breast cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; HRS-8080 (Primary) ; SHR-A2009 (Primary) ; Trastuzumab rezetecan (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shandong Shengdi Pharmaceutical

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com